Results 21 to 30 of about 4,667 (238)
Disseminated fungal infection in a patient receiving zanubrutinib
Clinical Case Reports, 2023 Key Clinical Message We report a case of fatal disseminated aspergillosis in the setting of administration of zanubrutinib, a second‐generation Bruton's tyrosine kinase inhibitor thought to have a lower rate of immunosuppression‐related side effects.
Madalyn Walsh +3 more
doaj +1 more source
Медицинская иммунология, 2023 Bruton's tyrosine kinase (BTK) inhibitors represent a class of drugs that have demonstrated their efficacy and safety in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphomas who were considered refractory to any previously used type of ...
Yu. S. Torshina +4 more
doaj +1 more source
Managing toxicities of Bruton tyrosine kinase inhibitors [PDF]
Hematology, 2020 Abstract Inhibition of Bruton’s tyrosine kinase (BTK) has revolutionized the treatment landscape for patients with chronic lymphocytic leukemia (CLL). By targeting this critical kinase in proximal B-cell receptor signaling, BTK inhibitors (BTKis) impair cell proliferation, migration, and activation of NF-κB.
Nicole Lamanna, Andrew Lipsky
openaire +2 more sources
Bruton tyrosine kinase inhibitors for multiple sclerosis
Nature Reviews Neurology, 2023 Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated worsening of disability, which is assumed to be mainly associated with transient infiltration of peripheral immune cells into the central nervous system (CNS). However, approved therapies are less effective at slowing disability accumulation in patients with MS ...
Julia Krämer +3 more
openaire +2 more sources
PLoS ONE, 2017 Activated B-cell-like diffuse large B-cell lymphoma relies on B-cell receptor signaling to drive proliferation and survival. Downstream of the B-cell receptor, the key signaling kinases Bruton's tyrosine kinase and phosphoinositide 3-kinase δ offer ...
Anella Yahiaoui +9 more
doaj +1 more source
Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors
American Journal of Clinical Dermatology, 2020 The development of Bruton's tyrosine kinase (BTK) inhibitors represents a major breakthrough in the treatment of chronic lymphocytic leukemia and other B cell malignancies. The first-generation inhibitor ibrutinib works by covalent irreversible binding to BTK, a non-receptor tyrosine kinase of the TEC (transient erythroblastopenia of childhood) family ...
Sibaud, Vincent +5 more
openaire +3 more sources
A covalent BTK ternary complex compatible with targeted protein degradation
Nature Communications, 2023 Bridging covalent ligand discovery with chimeric degrader design has emerged as a mechanism to target proteins that lack enzymatic activity or are intractable.
James Schiemer +8 more
doaj +1 more source
Switching immune signals on and off
eLife, 2015 Bruton's tyrosine kinase, an enzyme that is important for B cell function, can be activated in a number of ways.
Nam Chu, Philip A Cole
doaj +1 more source
Haematologica, 2015 Chronic lymphocytic leukemia is a malignancy of mature auto-reactive B cells. Genetic and functional studies implicate B-cell receptor signaling as a pivotal pathway in its pathogenesis.
Adrian Wiestner
doaj +1 more source
A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase
Royal Society Open Science, 2021 Bruton's tyrosine kinase (BTK) plays a vital role in mature B-cell proliferation, development and function. Its inhibitors have gradually been applied for the treatment of many B-cell malignancies. However, because of treatment-associated drug resistance
Simei Qiu, Yunfeng Liu, Quhuan Li
doaj +1 more source